Jakeb Riggle
Pulmonary Disease · Lincoln, NENPI 1710336342
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (54.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 63.6% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $10,894, more than ten times the $115 reported in 2019.
Across 116 payments — averaging $113.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Sanofi$2K
- AstraZeneca$921
- La Jolla Pharmaceutical Company$260
- Boehringer Ingelheim$252
- Grifols USA, LLC$230
- plus $1K from 22 others
What the payments were for
- Consulting fees$1,58112%
- Travel & lodging$1,30310%
- Food & beverage$3,17124%
- Education$7,09954%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $8,366 |
| Sanofi | 9 | $1,712 |
| AstraZeneca | 16 | $921 |
| La Jolla Pharmaceutical Company | 4 | $260 |
| Boehringer Ingelheim | 9 | $252 |
| Grifols USA, LLC | 9 | $230 |
| Regeneron Healthcare Solutions, Inc. | 4 | $203 |
| Actelion Pharmaceuticals US, Inc. | 6 | $171 |
| Harmony Biosciences LLC | 8 | $161 |
| GSK | 4 | $158 |
| United Therapeutics Corporation | 2 | $145 |
| Amgen | 8 | $132 |
| Jazz Pharmaceuticals Inc. | 4 | $63 |
| Resmed Corp | 1 | $48 |
| Insmed, Inc. | 3 | $48 |
| Baxter Healthcare | 2 | $44 |
| Verona Pharma, Inc. | 2 | $39 |
| Electromed, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $16 |
| Merck | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,154 in reported general payments places this provider in the 80th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 148 | $110,366 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 154 | $83,215 |
| Advair HfaFluticasone Propion/Salmeterol | 119 | $54,807 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $51,777 |
| Dupixent PenDupilumab | 11 | $41,162 |
| Pirfenidone | 22 | $40,310 |
| SymbicortBudesonide/Formoterol Fumarate | 91 | $25,452 |
| Spiriva RespimatTiotropium Bromide | 32 | $18,864 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 57 | $10,395 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $10,068 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,122 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $7,728 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,669 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,239 |
| DuleraMometasone/Formoterol | 11 | $4,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $921 | $143,546259 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Striverdi Respimat | $252 | $105,449199 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $158 | $79,648135 claims |
| MerckDulera | $16 | $4,12311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Lincoln
- Ryan MartinLincoln$600K
- Douglas FiedlerLincoln$23K
- Kevin ReichmuthLincoln$22K
- Harvey HopkinsLincoln$18K
- William JohnsonLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
- Jeffrey JarrettLincoln$5K
- Sean BarryLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.